News & Updates
Filter by Specialty:
Psychedelic drugs show promise for anxiety, depression
Use of psychedelic drugs appears to have some benefits in reducing anxiety and depressive symptoms among patients with cancer or other life-threatening diseases, reports a study.
Psychedelic drugs show promise for anxiety, depression
08 Jun 2023
Is liposomal irinotecan superior to topotecan in relapsed small cell lung cancer?
Treatment with liposomal irinotecan in adults with relapsed small cell lung cancer (SCLC) achieves similar overall survival (OS) when compared with topotecan, but the former is associated with a higher overall response rate (ORR), according to the results of RESILIENT, randomized, open-label phase III trial.
Is liposomal irinotecan superior to topotecan in relapsed small cell lung cancer?
07 Jun 2023
OPT-302 2.0 mg plus ranibizumab leads to superior vision gains in nAMD
Treatment with 2.0-mg OPT-302, a biologic inhibitor of vascular endothelial growth factor (VEGF)-C and D, in combination with ranibizumab, an anti‒VEGF-A inhibitor, results in greater vision gains when compared with the current standard of care for neovascular age-related macular degeneration (nAMD), reports a study. In addition, the combined therapy has an acceptable safety profile.
OPT-302 2.0 mg plus ranibizumab leads to superior vision gains in nAMD
05 Jun 2023
First-line TB treatment: Faropenem rivals ethambutol in efficacy, with fewer side effects
Faropenem, when used in combination with the other standard treatment drugs for the first-line treatment of tuberculosis (TB) infection, appears to be noninferior to ethambutol, with faropenem having the added benefit of lower frequency of adverse events (AEs), according to the results of an open-label study in China.